Navigation Links
Valeant Pharmaceuticals Announces Preliminary Results From Its Phase IIa Retigabine Study for the Treatment of Postherpetic Neuralgia (PHN)
Date:8/24/2009

ALISO VIEJO, Calif., Aug. 24 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE: VRX) today announced preliminary results from its Phase IIa proof-of-concept clinical trial of retigabine for the treatment of pain associated with postherpetic neuralgia (PHN), a painful and common complication of shingles. While retigabine was generally well tolerated, the study did not meet its pre-specified primary efficacy endpoint. Further detailed analyses are warranted and are ongoing.

"As is typical in many proof-of-concept studies, these results are inconclusive at this time with regard to the potential utility of retigabine in PHN patients," stated J. Michael Pearson, chairman and chief executive officer. "The treatment duration was relatively short and with limited statistical powering for the study overall. There are many additional analyses that have yet to be undertaken and these will be performed over the next several months. Moreover, given that the provisional results from this study will not impact the submission of our New Drug Application for retigabine in epilepsy, we remain focused on the submission as our number one priority."

The study was a randomized, double-blind, placebo-controlled Phase IIa proof-of-concept study with 187 patients randomized 2:1 of retigabine versus placebo for a treatment period of up to 10 weeks. The study was conducted in approximately 50 trial locations. Study patients were titrated to their individually determined maximum tolerated dose within the range of 300 mg to 900 mg per day. The primary outcome assessment was the comparison of the average pain intensity over the last seven days of maintenance therapy with retigabine versus placebo. Pain intensity was measured on a standard 0 - 10 numerical rating scale.

About PHN

PHN is a painful complication of Herpes Zoster, a condition commonly known as "shingles." Shingles results from a reactivation of the Varicella Zoster virus, the same agent that causes chicken pox. Patients with shingles typically have a painful blistering rash that lasts for several weeks. PHN occurs when nerve fibers are damaged during an outbreak of shingles, causing chronic and often excruciating pain that may continue for months or years. Currently available treatments for PHN include topical medications, over-the-counter analgesics, tricyclic antidepressants and antiepileptics.

About Retigabine

Retigabine, a first-in-class neuronal potassium channel opener, is currently in late-stage development as an adjunctive treatment for patients with partial-onset seizures. In Phase III epilepsy trials, retigabine was shown to be efficacious with a demonstrated reduction in monthly seizure rates.

Retigabine Important Note

Retigabine has not been found by the Food and Drug Administration (FDA) or any other regulatory agency to be safe or effective in the diagnosis, mitigation, treatment or cure of any disease or illness. It may not be sold or promoted in the United States unless and until the FDA has approved a NDA. Similar restrictions apply in other countries.

The most common side effects associated with retigabine to date include somnolence, dizziness, confusion, speech disorder, vertigo, tremor, amnesia, abnormal thinking, abnormal gait, paresthesia, diplopia, incoordination, nervousness, abnormal vision, asthenia, headache, nausea and diarrhea.

About Valeant

Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.valeant.com.

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements, including, but not limited to, statements regarding retigabine's potential in the treatment of postherpetic neuralgia and the impact of this clinical study on the filing of the New Drug Application. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the company's most recent annual or quarterly report filed with the Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

(Logo:http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO)

    Contact:
    Laurie W. Little
    Valeant Pharmaceuticals
    949-461-6002
    laurie.little@valeant.com


'/>"/>
SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Valeant Pharmaceuticals Reports Second Quarter Financial Results
2. Valeant to Acquire Tecnofarma, A Mexican Generic Company
3. Valeant Pharmaceuticals to Announce 2009 Second Quarter Results on August 4, 2009
4. Valeant Grants Schering-Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal
5. Valeant Announces Increase to Securities Repurchase Program
6. Valeant to Acquire Polish Dermatology Company
7. Valeant Pharmaceuticals to Present at Bank of America and Merrill Lynch 2009 Health Care Conference
8. Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting
9. Valeant Pharmaceuticals to Announce 2009 First Quarter Results on May 5, 2009
10. Valeant Pharmaceuticals Appoints President of Valeant Pharmaceuticals International
11. Valeant Pharmaceuticals to Present at Cowen and Company 29th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... 2017 , ... “A Prophets Bones”: a thrilling adventure that reveals the mystery of Kevin’s purpose. ... that his parents and teachers had asked of him that he had neglected to do, ... defy the Almighty Creator. There were some who would have felt themselves to be special ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who have sleep apnea ... with or without a referral. Sleep apnea is often left untreated because patients are ... headaches and chronic snoring. , Dr. Braasch seeks to raise awareness of sleep ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... custom smile makeovers without requiring a referral. Trimble Dental offers a ... treatment, cosmetic dentistry and dental implants. Whether patients have discolored, crooked or missing ...
(Date:3/27/2017)... ... 27, 2017 , ... Drs. Justin Kolnick, Kara Diamond, Randall Barton, Keith Hope ... the key role this treatment plays in protecting oral health, along with the benefits ... those who need a root canal in White Plains, NY or their second location ...
(Date:3/27/2017)... ... 2017 , ... This is the second major release since ... 2014. It is the culmination of collaborative efforts by members of the OSEHRA ... Member Zato Health co-funded the ONC certification and provided key technical support throughout ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 2017 FinancialBuzz.com News Commentary  ... Based on New Frontier Data,s sales ... cannabis is legal will generate $655 million in taxes on retail ... specific taxes, such as Washington State,s 37% ... from state sales taxes that are applied on all retail sales. ...
(Date:3/27/2017)... 2017 BioLineRx Ltd. (NASDAQ/TASE: BLRX), a ... that AGI-134, an immunotherapy for the treatment of multiple cancers, ... be featured at the upcoming American Association for Cancer ... to be held on April 1-5, 2017. ... An abstract ...
(Date:3/27/2017)... 27, 2017   Pulmatrix, Inc . (NASDAQ: PULM), a ... serious pulmonary diseases, today announced that it has added two ... and asthma to its Scientific Advisory Board . ... Richard B. Moss , MD, former chief of the Pediatric ... Fibrosis Center at Stanford University, and ...
Breaking Medicine Technology: